AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls
This study validates the MG-specific serum proteomic biomarkers AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 and identifies signatures associated with severity, onset, and treatment. These findings support the use of blood-based biomarkers for monitoring and stratification in MG clinical trials and care.
Authors
- Sarah Hoffmann (ORCID: https://orcid.org/0000-0001-9549-2594)
- Amol K. Bhandage (ORCID: https://orcid.org/0000-0002-7116-0939)
- Niclas Eriksson (ORCID: https://orcid.org/0000-0002-2152-4343)
- Frauke Stascheit (ORCID: https://orcid.org/0000-0001-5306-7880)
- Katja Gabrysch (ORCID: https://orcid.org/0009-0003-4234-8814)
- Anna Rostedt Punga (ORCID: https://orcid.org/0000-0002-2178-9413)
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Y.‐M. Huang (ORCID: https://orcid.org/0009-0005-2617-2083)
- Carla Dusemund (ORCID: https://orcid.org/0000-0001-6477-8901)
Institutions
- Uppsala University (SE)
- Uppsala University Hospital (SE)
- Humboldt-Universität zu Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1111/ene.70426
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Myasthenia Gravis Foundation of America
- Familjen Erling-Perssons Stiftelse
- Deutsche Forschungsgemeinschaft
- Akademiska Sjukhuset
- Uppsala Universitet